Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

69 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Molecular Profiling-Selected Therapy for Treatment of Advanced Pancreaticobiliary Cancer: A Retrospective Multicenter Study.
Epelbaum R, Shacham-Shmueli E, Klein B, Agbarya A, Brenner B, Brenner R, Gez E, Golan T, Hubert A, Purim O, Temper M, Tepper E, Voss A, Russell K, Dvir A, Soussan-Gutman L, Stemmer SM, Geva R. Epelbaum R, et al. Among authors: agbarya a. Biomed Res Int. 2015;2015:681653. doi: 10.1155/2015/681653. Epub 2015 May 28. Biomed Res Int. 2015. PMID: 26161408 Free PMC article.
Efficacy and Safety of BRAF Inhibitors With or Without MEK Inhibitors in BRAF-Mutant Advanced Non-Small-Cell Lung Cancer: Findings From a Real-Life Cohort.
Dudnik E, Bar J, Peled N, Bshara E, Kuznetsov T, Cohen AY, Shochat T, Nechushtan H, Onn A, Agbarya A, Moskovitz M, Keren S, Popovits-Hadar N, Urban D, Mishaeli M, Rabinovich NM, Brenner R, Zer A, Rotem O, Roisman LC, Wollner M; Israel Lung Cancer Group. Dudnik E, et al. Among authors: agbarya a. Clin Lung Cancer. 2019 Jul;20(4):278-286.e1. doi: 10.1016/j.cllc.2019.03.007. Epub 2019 Apr 5. Clin Lung Cancer. 2019. PMID: 31060855
Treatment of Rare Mutations in Patients with Lung Cancer.
Taha T, Khoury R, Brenner R, Nasrallah H, Shofaniyeh I, Yousef S, Agbarya A. Taha T, et al. Among authors: agbarya a. Biomedicines. 2021 May 11;9(5):534. doi: 10.3390/biomedicines9050534. Biomedicines. 2021. PMID: 34064757 Free PMC article. Review.
FGFR Fusions as an Acquired Resistance Mechanism Following Treatment with Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors (EGFR TKIs) and a Suggested Novel Target in Advanced Non-Small Cell Lung Cancer (aNSCLC).
Raphael A, Dudnik E, Hershkovitz D, Jain S, Olsen S, Soussan-Gutman L, Ben-Shitrit T, Dvir A, Nechushtan H, Peled N, Onn A, Agbarya A, On Behalf Of The Israel Lung Cancer Group. Raphael A, et al. Among authors: agbarya a. J Clin Med. 2022 Apr 28;11(9):2475. doi: 10.3390/jcm11092475. J Clin Med. 2022. PMID: 35566609 Free PMC article.
BRAF Mutant Lung Cancer: Programmed Death Ligand 1 Expression, Tumor Mutational Burden, Microsatellite Instability Status, and Response to Immune Check-Point Inhibitors.
Dudnik E, Peled N, Nechushtan H, Wollner M, Onn A, Agbarya A, Moskovitz M, Keren S, Popovits-Hadari N, Urban D, Mishaeli M, Zer A, Allen AM, Rabinovich NM, Rotem O, Kuznetsov T, Shochat T, Roisman LC, Bar J; Israel Lung Cancer Group. Dudnik E, et al. Among authors: agbarya a. J Thorac Oncol. 2018 Aug;13(8):1128-1137. doi: 10.1016/j.jtho.2018.04.024. Epub 2018 Apr 30. J Thorac Oncol. 2018. PMID: 29723688 Free article.
69 results